Boshoff to succeed Dolsten as Pfizer CSO
Plus: Hwang joins Metaphore, Flagship and updates from FDA, MHRA, ArrePath, ABT, Unnatural, Thryv and more
Pfizer Inc. (NYSE:PFE) named Chief Oncology Officer and EVP Chris Boshoff to succeed Mikael Dolsten as CSO and president, R&D, effective Jan. 1. The company added that Roger Dansey will become interim chief oncology officer effective the same date, and retire once a permanent successor has been selected. Joining Pfizer is Johanna Bendell, who will become chief development officer, oncology starting in 2025. Bendell is global head oncology, Pharma Research and Early Development (pRED) at Roche (SIX:ROG; OTCQB:RHHBY).
Flagship Pioneering hired Angela Hwang as CEO-partner and CEO of Metaphore Biotechnologies Inc., which the VC launched in May to develop therapeutics that mimic natural molecular interactions, but have improved biophysical features. Hwang recently left Pfizer after almost 30 years with the company, most recently as chief commercial officer and president of its global biopharmaceuticals business...